Skip to content
HabitSeek
Back to results

Mediterranean-style eating

A dietary pattern built around vegetables, fruit, legumes, whole grains, nuts, olive oil and fish, with red and processed meat limited.

At a glance

  • Evidence: Two large, long-term randomized trials support fewer major cardiovascular events in the populations studied.Major cardiovascular events (myocardial infarction, stroke, revascularisation, cardiovascular death) · Moderate certainty · Randomized intervention
  • What’s uncertain: One dominant trial required re-analysis after protocol deviations; the other was single-centre and included relatively few women.
  • First step: Build meals around vegetables, fruit, legumes, whole grains, nuts, olive oil and fish, with red and processed meat limited.
  • Before you try it: Olive oil and nuts are energy-dense; the weight-loss trial used an energy-restricted version of this pattern, so added fats need to fit your overall energy intake. All precautions

Takeaway

Randomized trials support fewer major cardiovascular events with a Mediterranean-style eating pattern in adults at high cardiovascular risk, along with modest weight and risk-factor improvements. It does not reliably change mortality in the trial evidence, and no large second primary-prevention trial has replicated the event result.

Mediterranean food served at a restaurantDiscussed byChristopher GardnerView statements ↓
NutritionLong-term healthVaries · Moderate · Moderate
Reviewed Sep 23, 2026
Save

Scientific evidence

What the research shows

Outcome assessments based on research, including its uncertainties and limitations.

Major cardiovascular events (myocardial infarction, stroke, revascularisation, cardiovascular death)

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: randomised trials

Two large long-term randomized trials in different populations point the same way.

Population: Adults at high cardiovascular risk but free of cardiovascular disease at baseline (PREDIMED: 55-80 years, 57% women, Spain) and patients with established coronary heart disease (CORDIOPREV: mean age 59.5 years, 82.5% men), plus 38 prospective cohorts and 2 further RCTs in a pooled analysis that included people with diabetes.

Research details

Summary

Two large long-term randomized trials in different populations point the same way. In PREDIMED (7447 high-risk adults without cardiovascular disease, median 4.8 years), the revised 2018 analysis found fewer major cardiovascular events with a Mediterranean diet plus extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or plus nuts (HR 0.72, 95% CI 0.54 to 0.95) than with a reduced-fat control diet. In CORDIOPREV (1002 patients with established coronary heart disease, 7 years), the Mediterranean diet beat a low-fat diet for the composite endpoint (adjusted HR 0.719 to 0.753). Pooled cohort data from populations that include people with diabetes agree in direction (stroke incidence RR 0.80, 95% CI 0.71 to 0.90; CHD incidence RR 0.73, 0.62 to 0.86).

Why this certainty

Rated Moderate rather than Strong: direction is consistent across two large randomized trials and multiple cohort syntheses, and PREDIMED survival was robust to excluding non-compliant participants, but only one large primary-prevention RCT exists, it carries acknowledged randomization problems, CORDIOPREV was small and sex-imbalanced, and the Cochrane review rated related clinical-event evidence low quality. Relevance is high because these are hard clinical endpoints, not surrogates.

Limitations

PREDIMED is the single dominant primary-prevention trial and required re-analysis after documented protocol deviations at 2 of 11 sites, 1588 participants being excluded in a sensitivity analysis. CORDIOPREV was single-centre with only 175 women and showed no benefit in women. Both trials used an active comparator diet rather than no intervention, so the estimate is relative. No second large primary-prevention RCT has replicated the composite endpoint.

Effect estimate

PREDIMED 2018 republication: HR 0.69 (95% CI 0.53 to 0.91) for Mediterranean diet with extra-virgin olive oil and HR 0.72 (95% CI 0.54 to 0.95) for Mediterranean diet with nuts versus control, median follow-up 4.8 years. CORDIOPREV: multivariable-adjusted HRs ranged from 0.719 (95% CI 0.541-0.957) to 0.753 (95% CI 0.568-0.998) over 7 years.

Sources for this outcome:

All-cause and cardiovascular mortality in prospective cohorts

Finding: Benefit supportedCertainty: Limitedstudies found a benefit from doing this

Evidence basis: observational studies (association, not proof of cause)

Closer adherence to a Mediterranean-style diet is associated with lower all-cause and cardiovascular mortality in prospective cohorts, but the evidence is observational and heterogeneous.

Population: Adults in prospective cohort studies: 29 prospective studies with 1,676,901 participants and 221,603 deaths in the dose-response analysis, and 41 reports (3 randomised trials and 38 cohorts) in the diabetes-inclusive synthesis.

Research details

Summary

The precise, dose-responsive mortality evidence for this dietary pattern is observational. A dose-response meta-analysis of 29 prospective studies with 1,676,901 participants and 221,603 deaths found a pooled hazard ratio for all-cause mortality of 0.90 (95% CI 0.89 to 0.91; I2 = 81.1%) per 2-point increment in adherence, with a stronger association in the Mediterranean region than outside it (HR 0.82 versus 0.92). A separate synthesis of 41 reports found cardiovascular mortality RR 0.79 (95% CI 0.77 to 0.82) for highest versus lowest adherence, in populations inclusive of individuals with diabetes. The authors of the dose-response analysis describe their own evidence as low quality, and the randomised estimates for mortality are null or imprecise (recorded in the separate outcome on mortality in randomised trials).

Why this certainty

Rated Limited rather than Moderate: the participant numbers are very large and the direction is consistent across independent syntheses, but the evidence is observational, heterogeneity is high, and the authors of the dose-response analysis grade their own evidence low quality. It is not Very limited because two independent syntheses agree on direction and magnitude for the same exposure, and the finding is biologically coherent with the randomised risk-factor results recorded in the other outcomes.

Limitations

Entirely observational, so residual confounding by socioeconomic position, overall diet quality and baseline health cannot be excluded, and adherence is self-reported. Heterogeneity was substantial (I2 = 81.1% for all-cause mortality). The authors call their own pooled estimate low-quality evidence, and the dose-response relationship was linear, which means the size of the benefit at any individual level of adherence is uncertain. The second synthesis was conducted in populations inclusive of people with diabetes and its cardiovascular mortality estimate therefore should not be transferred to general populations.

Effect estimate

All-cause mortality HR 0.90 (95% CI 0.89 to 0.91; I2 = 81.1%) per 2-point increment in adherence across 29 prospective studies (1,676,901 participants, 221,603 deaths); cardiovascular mortality RR 0.79 (95% CI 0.77 to 0.82) highest versus lowest adherence in cohorts of people with diabetes.

Sources for this outcome:

Mortality in randomised trials

Finding: Little/no effectCertainty: Limitedstudies found little or no effect

Evidence basis: randomised trials

In the randomised trials, Mediterranean-style diets showed no clear effect on all-cause or cardiovascular mortality, and the estimates were imprecise.

Population: Adults at high cardiovascular risk in PREDIMED, and 605 patients with established coronary heart disease in the Lyon Diet Heart Study; the Cochrane review pooled 30 randomised trials with 12,461 participants, of which the mortality data available for this comparison came from a small subset.

Research details

Summary

The randomised mortality evidence is null and imprecise rather than positive. The Cochrane review's own extraction of PREDIMED reports low-quality evidence of little or no effect of the Mediterranean-diet intervention compared with a low-fat diet on cardiovascular mortality (HR 0.81, 95% CI 0.50 to 1.32) or total mortality (HR 1.0, 95% CI 0.81 to 1.24) over 4.8 years. The one trial with a clearly positive mortality result is the Lyon Diet Heart Study, a small secondary-prevention trial in 605 patients with coronary heart disease followed for 46 months, in which advice to follow a Mediterranean diet plus supplemental canola margarine was associated with lower cardiovascular mortality (HR 0.35, 95% CI 0.15 to 0.82) and total mortality (HR 0.44, 95% CI 0.21 to 0.92), on low-quality evidence.

Why this certainty

Rated Limited and recorded as Little/no effect rather than as benefit: relevant randomised trials exist and reported mortality, but the pooled estimate from the largest primary-prevention trial is null with a confidence interval that includes a substantial benefit and a substantial harm, and the single positive trial is small, old and confounded by a supplied margarine. It is not Insufficient direct evidence because mortality was directly measured in randomised trials.

Limitations

The PREDIMED mortality estimates are the Cochrane reviewers' own analyses and differ from the trial's published primary-endpoint results, so the two must not be conflated; both confidence intervals cross 1. The Lyon trial was small, was conducted in secondary prevention, and supplemented the diet with canola margarine, so it does not isolate the dietary pattern. Most included trials did not report mortality at all, and the review found no trials reporting costs or health-related quality of life.

Effect estimate

PREDIMED (Cochrane extraction) versus low-fat diet: cardiovascular mortality HR 0.81 (95% CI 0.50 to 1.32), total mortality HR 1.0 (95% CI 0.81 to 1.24), low-quality evidence. Lyon Diet Heart Study: cardiovascular mortality HR 0.35 (95% CI 0.15 to 0.82), total mortality HR 0.44 (95% CI 0.21 to 0.92).

Sources for this outcome:

Body weight and cardiometabolic risk factors (waist circumference, blood pressure, glucose, lipids)

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: randomised trials

Modest weight loss was reported with a Mediterranean-style diet, but the effect came from the accompanying energy restriction, activity and behavioural support, not the dietary pattern alone.

Population: Overweight or obese adults aged 55-75 years with metabolic syndrome (PREDIMED-Plus, n = 626), 244,678 to 436,617 adults in prospective cohorts for overweight/obesity risk and 5-year weight change, and adults in 30 randomized trials included in the Cochrane review of Mediterranean-style diets.

Research details

Summary

A Mediterranean-style diet is compatible with modest weight loss and improves cardiometabolic risk markers, but the weight effect depends heavily on the overall programme. In PREDIMED-Plus, an intensive programme built on an energy-restricted Mediterranean diet plus physical activity and behavioural support produced a 12-month between-group weight difference of -2.5 kg (95% CI -3.1 to -1.9), with 5% or greater weight loss in 33.7% versus 11.9%. Cohort data are directionally consistent: each 1-point higher adherence score was associated with 0.04 kg less weight gain over 5 years and RR 0.91 for overweight/obesity. Cochrane also found small reductions in blood pressure and total cholesterol.

Why this certainty

Rated Moderate: the randomized intervention shows a clear, precisely estimated weight difference and improvements in waist circumference, fasting glucose, triglycerides and HDL cholesterol (P < 0.002), and cohort dose-response data agree in direction. Downgrades reflect the bundling of diet with exercise and behavioural support in the trial, short 12-month follow-up, reliance on observational data for long-term weight change, and heterogeneity across cohort analyses.

Limitations

The PREDIMED-Plus weight result comes from a multifactorial intervention (energy restriction plus physical activity plus behavioural support), so the weight loss cannot be attributed to the dietary pattern alone, and follow-up was only 12 months. Cohort weight-change estimates are very small (-0.04 kg per score point over 5 years) with heterogeneity in the overweight/obesity analyses (I2 = 44.7%). The obesity-only cohort estimate was not statistically significant (RR 0.68, 95% CI 0.43, 1.10).

Effect estimate

PREDIMED-Plus at 12 months: mean between-group difference in weight change -2.5 kg (95% CI -3.1 to -1.9); weight loss of 5% or more in 33.7% versus 11.9%. Cohorts: -0.04 kg weight change over 5 years per 1-point higher Mediterranean diet score (95% CI -0.07 to -0.02) and RR 0.91 (95% CI 0.88, 0.94) for overweight/obesity. Cochrane: systolic blood pressure -2.99 mmHg (95% CI -3.45 to -2.53), diastolic -2.0 mmHg (95% CI -2.29 to -1.71), total cholesterol -0.16 mmol/L (95% CI -0.32 to 0.00).

Sources for this outcome:

What people say

Who discusses this?

Public statements, with positions specific to each source and topic. These views do not determine the scientific evidence assessment.

What the research shows ↑

Practical steps and precautions

How to try it

  1. Build meals around vegetables, fruit, legumes, whole grains, nuts, olive oil and fish, with red and processed meat limited.
  2. If you want a concrete starting point, treat a daily handful of nuts or a few tablespoons of olive oil as an editorial suggestion rather than a prescribed dose.
  3. Expect the cardiovascular evidence to come mainly from adults at high risk followed for about five years; effects in otherwise healthy adults are less certain.
  4. Pair the pattern with an energy-restricted intake if weight loss is your goal, because the weight-loss trial restricted energy as well as changing the diet.

Precautions

  • Olive oil and nuts are energy-dense; the weight-loss trial used an energy-restricted version of this pattern, so added fats need to fit your overall energy intake.
  • Wine is not an essential component of the pattern, and nothing in the evidence reviewed here justifies starting to drink alcohol for health reasons.
  • The randomized evidence is about lowering risk alongside usual medical care, not about replacing prescribed treatment.

References

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.

Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. · The New England Journal of Medicine · 2018

Multicentre randomized controlled trial (corrected and republished article; 2018 republication of the retracted 2013 report)Verified from abstract
Open original source

Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.

Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, et al. · The Lancet · 2022

Single-centre randomized controlled trial (secondary prevention, 7-year follow-up)Verified from abstract
Open original source

Mediterranean diet, cardiovascular disease and mortality in diabetes: A systematic review and meta-analysis of prospective cohort studies and randomized clinical trials.

Becerra-Tomás N, Blanco Mejía S, Viguiliouk E, Khan T, Kendall CWC, Kahleova H, et al. · Critical Reviews in Food Science and Nutrition · 2020

Systematic review and meta-analysis of prospective cohort studies and randomized clinical trialsVerified from abstract
Open original source

Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease.

Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, et al. · Cochrane Database of Systematic Reviews · 2019

Cochrane systematic review and meta-analysis of randomized controlled trials (review update)Verified from abstract
Open original source

Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90.

Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. · The New England Journal of Medicine · 2018

Retraction and republication notice (indexed bibliographic record)Verified from abstract
Open original source

Adherence to the Mediterranean Diet in Relation to All-Cause Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.

Soltani S, Jayedi A, Shab-Bidar S, Becerra-Tomás N, Salas-Salvadó J · Advances in Nutrition · 2019

Systematic review and dose-response meta-analysis of prospective cohort studiesVerified from abstract
Open original source

Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial.

Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, et al. · Diabetes Care · 2019

Randomized controlled trial (12-month results of PREDIMED-Plus)Verified from abstract
Open original source

Adherence to the Mediterranean Diet, Five-Year Weight Change, and Risk of Overweight and Obesity: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.

Lotfi K, Saneei P, Hajhashemy Z, Esmaillzadeh A · Advances in Nutrition · 2022

Systematic review and dose-response meta-analysis of prospective cohort studiesVerified from abstract
Open original source

Community

Discussion

Have you tried this? What helped or made it difficult?

Reader experiences are separate from the scientific evidence. Explore all discussions

No discussions yet.

Be the first to ask a question or share your experience.

Sign in to vote or join the discussion.

Related habits

Explore other habits in a shared category. Each has its own evidence and precautions.

Editorial history and review method

Revision 4 · Approved for publication · Codex (publication approval explicitly authorized by site owner; category migration)

Prepared and checked with AI. Publication approval does not imply independent expert review. Request a correction.

Audit correction pass (group 6). The single 'cardiovascular-and-all-cause-mortality' outcome was split into two, because its evidenceBasis was recorded as 'Randomized intervention' while its own summary and effectEstimate led with the observational stream (soltani-2019 dose-response cohort data) and its randomised estimates were null or imprecise. New outcome 'mortality-cohort-adherence' (Benefit supported / Limited / Observational association) carries the cohort estimates; new outcome 'mortality-randomised-trials' (Little/no effect / Limited / Randomized intervention) carries the Cochrane extraction of PREDIMED and the Lyon Diet Heart Study. major-cardiovascular-events summary corrected: the cohort sentence now names the diabetes-inclusive population and adds both confidence intervals (stroke incidence RR 0.80, 95% CI 0.71 to 0.90; CHD incidence RR 0.73, 0.62 to 0.86). body-weight-and-cardiometabolic-risk-factors headline now states that the weight effect comes from an energy-restricted diet combined with physical activity and behavioural support rather than from the dietary pattern alone, matching the limitation text. The card outcome is unchanged (major-cardiovascular-events). A second reviewer must re-check: (1) whether the catalogue prefers one mixed-label mortality outcome over this two-outcome split, since the split changes the outcome list for a Standard-coverage entry; (2) that the new randomised-mortality outcome is not read as evidence of harm, because both confidence intervals include the null; (3) the open item carried forward from creation — the PREDIMED 2018 republication abstract states 7447 participants were assigned while rees-2019 says 'the PREDIMED (7747 randomised) intervention', and the discrepancy is in the sources rather than in this entry, so the correct denominator still needs an outside decision; (4) that estruch-2018b is an indexed retraction notice with no abstract and is cited only so the retraction history stays visible; and (5) that the CORDIOPREV sex finding (no difference in 175 women) is still recorded in the events outcome. Publication release 2026-10-04: site owner authorized a bounded AI audit and release of this exact revision. See docs/release-audit-2026-10-04.md for source-check findings and limits. No independent health-professional or peer review is claimed. Category migration 2026-10-04: removed the separate goals field; categories: Nutrition, Long-term health → Nutrition, Long-term health. Research assessments, sources, guidance, precautions, and evidence review dates are unchanged. This revision awaits publication approval; no new evidence review is claimed. Publication approval 2026-10-04: site owner explicitly accepted all current category-migration revisions for deployment and requested that remaining limitations be retained in docs/content-review-backlog.md. Approval applies to this exact content revision. No new evidence review, independent expert review, or clinical validation is claimed; existing precautions and disclosures remain in effect.